(Reuters) -The U.S. Food and Drug Administration approved IntraBio’s drug for a rare and fatal genetic disorder, the health regulator said on Tuesday, just days after […]
For Immediate Release: September 24, 2024 Today, the U.S. Food and Drug Administration approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease […]
For Immediate Release: September 24, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the […]
TOPLINE: Patients with breast cancer carrying TP53 pathogenic variants face an 8.8% cumulative risk for developing sarcoma within 15 years of receiving radiotherapy. However, the 10-year […]
Digital pathology assisted by artificial intelligence (AI) has the potential to transform the diagnosis and treatment of fibrotic liver disease in the next few years and […]
MADRID — Emerging data pointed to the urgent need for cardiovascular risk reduction in all adults with type 1 diabetes (T1D), including those who are young […]
It may come as a surprise but Europe has a malnutrition problem. It affects millions of people, yet it is deeply underestimated and requires a shared […]
New York — The diagnosis of central centrifugal cicatricial alopecia (CCCA), the most common form of cicatrizing hair loss in Black women, is still being missed, […]
Internist Vincent Martin, MD, said every primary care clinician should know about calcitonin gene-related peptide (CGRP) monoclonal antibodies for preventing migraines. These newer drugs are changing […]
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPTReject
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.